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Clinician’s Corner
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CASE PRESENTATION
A 3-month-old term nonconsanguineous female infant was found 
to have a bulging anterior fontanelle at her 2-month visit. Two 
weeks later upon presenting to the emergency room with a viral 
illness, investigations showed hypophosphatemia 0.49 mmol/L 
(1.3 to 2.6  mmol/L), normocalcemia 2.65  mmol/L (2.24 to 
2.74 mmol/L), and parathyroid hormone (PTH) <0.3 pmol/L 
(1.6 to 6.9 pmol/L). Workup for hypophosphatemia including 
head and renal ultrasounds was unremarkable. X-rays showed 
flaring of metaphyses in femurs, tibiae, and fibulae, and she was 
started on phosphate (3  mmol 4 times a day) and vitamin D 
(Calcitriol equivalent to 1,000 IU daily) for presumed congen-
ital rickets. Two weeks into treatment, she was admitted to the 
Paediatric Critical Care Unit with status epilepticus secondary to 
hypocalcemia with an ionized calcium of 0.97 mmol/L (1.09 to 
1.3 mmol/L). 1,25-Dihydroxy Vitamin D levels returned at >480 
pmol/L (60 to 208 pmol/L) ruling out congenital rickets. She 
had significant anemia with hemoglobin 85 g/L (100 to 140 g/L), 
thrombocytopenia 131×10^9/L (150 to 400×10^9/L), and 
blasts (0.141×10^9/L) on peripheral smears. Clinical examina-
tion revealed nystagmus and no hepatosplenomegaly. Skeletal 
survey showed a new finding of diffuse bone sclerosis along with 
fraying of metaphyses diffusely (Figures 1 and 2). A head mag-
netic resonance imaging demonstrated enlarged lateral and third 
ventricles (Figure 3). A bone marrow biopsy sample was difficult 
to obtain. However, findings of hypophosphatemia, hypocalce-
mia, bicytopenia, and x-ray abnormalities prompted molecular 
studies, which confirmed the diagnosis.
Figure 1. Extensive sclerosis of femurs and fraying of metaphyses
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DIAGNOSIS: MALIGNANT INFANTILE 
OSTEOPETROSIS
Next-generation sequencing identified a pathogenic muta-
tion in the T-cell immune regulator 1 (TCIRG1) gene 
(c.1674-1G>A), which confirmed the suspicion of malig-
nant infantile osteopetrosis (MIO). This gene is associ-
ated with an autosomal recessive form of MIO. As only one 
pathogenic mutation was found, deletion/duplication and 
whole-exome sequencing were undertaken to identify a 
second mutation, however, no relevant abnormalities were 
identified. It is possible a second TCIRG1 mutation is pres-
ent which current genetic testing technology cannot detect, 
as previous reports have described patients with a clinical 
phenotype of MIO with only one identified mutation (1). 
With the corresponding clinical phenotype, we proceeded 
with definitive management for MIO, which is bone marrow 
transplantation (BMT). The patient’s brother was a favour-
able HLA match. In preparation for transplant, a CT head 
demonstrated obstructive hydrocephalus with transependy-
mal edema and splaying of the skull fissures. The patient had 
a ventriculo-peritoneal shunt inserted with subsequent res-
olution of hydrocephalus. She underwent a successful allo-
geneic BMT and is currently in follow-up but unfortunately, 
has ongoing visual impairment.
Autosomal recessive MIO is the most severe form of osteo-
petrosis, with an estimated annual incidence of 1/100,000 to 
500,000. It is a disorder of bone remodelling caused by failure 
of osteoclasts to resorb immature bone (2). This leads to ab-
normal bone marrow cavity formation and subsequent dis-
placement of hematopoietic cells from the medullary cavity, 
resulting in extramedullary hematopoiesis and possible bone 
marrow failure (anemia, infection, and blasts on peripheral 
smear). Impaired bone remodelling can cause narrowing of cra-
nial nerve foramina resulting in optic nerve compression, visual 
impairment, or obstructed cerebrospinal fluid flow and hydro-
cephalus. Abnormal remodelling of primary bone to lamellar 
bone leads to bones that are prone to fracture. These abnormal-
ities result in the classic features of the disease: bone marrow 
failure, visual impairment, and fractures.
Children often present within the first 3 months of life, fre-
quently due to parental concern for the child’s vision. Other 
common presentations include failure to thrive and recurrent 
infections (3). Less common presentations include hypocalce-
mic seizures, bruising, fractures, nasal congestion, and abnor-
mal craniofacial appearance. A diagnosis of MIO relies strongly 
on clinical suspicion. Visual impairment, hypocalcemia, and 
anemia can suggest a diagnosis of MIO. Typical x-ray findings 
of sclerotic bony changes, as seen in our patient, can help sup-
port the diagnosis with confirmation of sclerosis through bone 
biopsy.
When assessing a neonate presenting with hypocalcemia, 
such as our patient, it is important to confirm that this is a true 
result using ionized calcium. Then, assess the status of other ex-
tended electrolytes including magnesium and phosphate, which 
if low, could indicate losses through either the GI or renal sys-
tems. A 24-hour urine sample could be considered to accurately 
assess potential losses. Concurrently, investigate for a potential 
endocrinologic cause by obtaining both PTH and 25-hydroxy 
vitamin D levels. An elevated PTH indicates a secondary 
Figure 2. Frayed metaphyses of humeral heads and scapula, expansion of 
anterior ribs at costochondral junctions. Figure 3. Enlarged lateral ventricles on magnetic resonance imaging.
70 Paediatrics & Child Health, 2020, Vol. 25, No. 2
hyperparathyroidism which has numerous causes including 
vitamin D-dependent rickets. In this case, vitamin D levels 
would be low. A low or inappropriately normal PTH along with 
a normal vitamin D level would indicate hypoparathyroidism, 
for which a separate workup would need to be initiated (2). If 
despite these investigations, a diagnosis is not clear, it is then 
worthwhile to consider rarer causes such as osteopetrosis.
Genetic investigation is needed to confirm the diagnosis. 
MIO is a heterogeneous disease with numerous possible asso-
ciated genetic loci. A  pathogenic heterozygous mutation in 
TCIRG1, as seen in our patient, has been associated with MIO. 
TCIRG1 codes for vacuolar H+ ATPase which plays an essen-
tial role in osteoclast function. Autosomal dominant forms of 
osteopetrosis are more benign.
Management of MIO involves supportive treatment until 
curative BMT. Patients with MIO can have severe pancy-
topenia and may become transfusion dependent. Failure 
to thrive is another common complication, which requires 
a team of allied health professionals to optimize growth in 
preparation for transplantation. Medical therapies including 
steroids, calcitriol and interferon gamma-1B have been stud-
ied; however, BMT is the only treatment shown to alter the 
disease’s course (4).
MIO has a high mortality rate in those with severe disease 
and bone marrow failure. A  common cause of early death is 
overwhelming infection. A  favourable prognosis is seen in 
patients who are not transfusion dependent and alive at age two 
(3). Timing of BMT can affect outcomes significantly, as delay 
can cause complications including visual loss and obstructive 
hydrocephalus. Although BMT will halt further disease pro-
gression, previous morbidity from bone remodelling cannot be 
reversed.
Hypophosphatemia is an unusual presenting symptom of MIO. 
The development of hypocalcemia in our patient eventually led to 
the diagnosis, as this along with her distinctive x-ray findings and 
signs of bone marrow failure are classic features of the disease.
CLINICAL PEARLS
1. Bony changes on plain films, including striking sclerosis, 
may be the first sign of MIO.
2. The combination of hypocalcemia, cytopenias, and bony ab-
normalities (on x-ray and clinical exam) may indicate early 
MIO.
3. Timely BMT can be life-saving in MIO and significantly de-
creases morbidity. Therefore, early recognition of this rare 
condition is essential and genetic counselling is important 
for the family.
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